Union Home Minister and Minister of Cooperation Shri Amit Shah extends his heartfelt greetings to all beneficiaries of Pradhan Mantri Bharatiya Jan Aushadhi Yojana (PMBJP) on Jan Aushadhi Diwas 2026

1. At a Glance

PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) is a Government of India scheme to provide quality generic medicines at affordable prices through dedicated outlets called Jan Aushadhi Kendras (JAKs) [S1][S2].
Run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, with implementing arm PMBI (Pharmaceuticals & Medical Devices Bureau of India) [S2].
Jan Aushadhi Diwas is observed annually on 7 March; 2026 marks the 8th edition [S1][S3].
Critical for GS-II (health, welfare schemes) and GS-III (pharma sector, generics).

2. Why in the News

On 7 March 2026, Union Home Minister & Minister of Cooperation Amit Shah greeted beneficiaries on Jan Aushadhi Diwas 2026 via X [S1].
He stated the scheme has saved citizens over ₹40,000 crore and that approximately 18,000 Jan Aushadhi Kendras are operational [S1].
Janaushadhi Saptah 2026 (week-long outreach) culminated in the 8th Janaushadhi Diwas observance [S3].

3. Background & Evolution

Launched November 2008 by Department of Pharmaceuticals (originally as "Jan Aushadhi Campaign"); re-launched and renamed PMBJP in 2015–16 under the Modi government [S2].
2019: Jan Aushadhi Diwas observance instituted (7 March) [S3].
2023: Cooperation Ministry roped in — store codes distributed to PACS (Primary Agricultural Credit Societies) across 5 states to run JAKs, integrating cooperatives into the scheme [S4].
FY 2023-24: Sales crossed ₹1,000 crore for the first time [S5].
2024-26: Rapid scale-up — 13,822 (Oct 2024) → 16,912 (June 2025) → ~18,000 (Mar 2026) JAKs [S2][S6].

4. Core Static Facts

Nodal Ministry: Ministry of Chemicals & Fertilizers → Department of Pharmaceuticals [S2].
Implementing Agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India), a society under DoP [S2].
Outlet name: Jan Aushadhi Kendra (JAK) / PMBJK.
Number of JAKs: ~18,000 (announced Mar 2026); 18,646 opened by 28 Feb 2026 [S1][S2].
Target: 25,000 JAKs by March 2027 [S6].
Product basket: 2,110 medicines + 315 surgical/consumables across 29 therapeutic categories [S2].
Price advantage: MRP 50–80% lower than branded equivalents [S2].
Cumulative savings to citizens: over ₹40,000 crore (March 2026 figure cited by HM); ~₹38,000 crore as of June 2025 [S1][S2].
JAK operator incentive: 10% of monthly purchases, capped at ₹10,000/month (additional incentives for SC/ST/Divyang/NE/aspirational district owners) [S2].
Quality assurance: Medicines from WHO-GMP compliant manufacturers; batch-tested at NABL-accredited labs [S2].
Diwas date: 7 March annually (commemorates 2019 PM interaction with beneficiaries) [S7].

5. Multi-Dimensional Analysis

Economic / Healthcare Financing - Out-of-pocket health expenditure (OOPE) in India remains high; generics through PMBJP directly reduce drug-cost burden, the largest component of OOPE [S2]. - Cumulative consumer savings of ~₹40,000 crore since inception [S1]. - Creates self-employment for kendra owners (pharmacist-led model) [S2].

Social / Equity - Targets poor and needy, esp. those on chronic medication (diabetics, cardiac, cancer) [S1][S2]. - Special incentive structure for SC/ST, Divyang, NE region, aspirational district entrepreneurs widens inclusion [S2].

Administrative / Federalism - Centrally Sponsored; relies on state cooperation for site allocation, esp. via district hospitals. - Cooperative angle (2023 onwards): ~PACS authorised to open JAKs — synergises with Ministry of Cooperation's PACS-revitalisation agenda [S4].

Scientific / Pharma Sector - Reinforces India's generic-drug strength ("Pharmacy of the World"). - Tackles information asymmetry — promotes prescribing by generic name (linked to MCI/NMC 2017 directive).

Governance / Awareness - Annual Jan Aushadhi Diwas (7 March) + Janaushadhi Saptah function as IEC campaigns to overcome public bias against generics [S3].

6. Recent Developments (2024-26)

Oct 2024: 13,822 JAKs operational [S6].
Feb 2025: 15,057 JAKs (Jan Aushadhi Diwas 2025 — 7th edition) [S8][S3].
June 2025: 16,912 JAKs; target of 25,000 by March 2027 reaffirmed [S6].
28 Feb 2026: 18,646 JAKs [S2].
7 March 2026: HM Amit Shah's greetings — 8th Jan Aushadhi Diwas; ₹40,000 cr cumulative savings milestone announced [S1].
Janaushadhi Saptah 2026: nationwide outreach week [S3].

7. Prelims Hooks

PMBJP launched: 2008; re-launched/renamed in 2015–16 [S2].
Implementing agency: PMBI (not NPPA, not CDSCO) [S2].
Parent Ministry: Chemicals & Fertilizers (Dept. of Pharmaceuticals) — NOT Ministry of Health & Family Welfare [S2].
Jan Aushadhi Diwas: 7 March; 2026 = 8th edition [S1][S3].
Outlets (Mar 2026): ~18,000 ; target 25,000 by March 2027 [S1][S6].
Product range: 2,110 medicines + 315 surgicals, 29 therapeutic categories [S2].
Price gap: 50–80% cheaper than branded medicines [S2].
Quality: WHO-GMP sourcing; NABL-accredited lab testing [S2].
Owner incentive: 10% of monthly purchases, max ₹10,000/month [S2].
Cumulative consumer savings: ₹40,000 crore+ (Mar 2026) [S1].
PACS as JAK operators: introduced via Ministry of Cooperation (2023) [S4].
FY 2023-24 sales crossed ₹1,000 crore [S5].

8. Mains Relevance

GS-II: Welfare schemes for vulnerable sections; Issues relating to development & management of Health.
GS-III: Pharmaceutical sector; Inclusive growth.

Plausible question stems: 1. "Affordable access to medicines is a precondition for Universal Health Coverage. Examine the role of PMBJP in reducing out-of-pocket health expenditure in India." (GS-II, 15 marks) 2. "Despite WHO-GMP compliance, public perception of generic medicines remains a barrier. Discuss the demand-side challenges of Jan Aushadhi Kendras and suggest reforms." (GS-II/III, 10 marks) 3. "Discuss the convergence between Ministry of Cooperation's PACS revitalisation and the Department of Pharmaceuticals' PMBJP, and its implications for rural healthcare." (GS-II, 15 marks)

9. Related Topics to Study Next

NPPA & DPCO 2013 — drug price control regime (complement to PMBJP).
Ayushman Bharat — PM-JAY & HWCs — primary care + insurance pillar of UHC.
National Health Policy 2017 — UHC framework.
Bulk Drug Parks / PLI for Pharma — supply-side support for generics.
PACS Revitalisation (Ministry of Cooperation) — multi-purpose PACS including JAKs.
NMC's generic-prescription directive (2017/2023) — physician-side push for generics.
CDSCO & WHO-GMP — drug quality regulation.
Out-of-Pocket Expenditure (OOPE) & National Health Accounts — measuring health financing.

10. Common Errors / Trap Areas

❌ Thinking PMBJP is under Ministry of Health & Family Welfare — it is under Chemicals & Fertilizers [S2].
❌ Confusing PMBI (implementing agency) with NPPA (price regulator) or CDSCO (drug standards regulator).
❌ Treating the 2008 launch as the Modi-era launch — original launch was 2008; re-launch was 2015 [S2].
❌ Mixing up Jan Aushadhi Diwas (7 March) with National Doctors' Day (1 July) or Ayushman Bharat Diwas (30 April).
❌ Assuming all medicines are 80% cheaper — the official figure is a range of 50–80% [S2].

11. Sources

[S1] Amit Shah greetings on Jan Aushadhi Diwas 2026 — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2236280 — (tier 1)
[S2] PMBJP overview / Expansion of PMBJKs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236292 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2242928 — (tier 1)
[S3] Jan Aushadhi Diwas 2025 / Saptah — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2108862 — (tier 1)
[S4] Amit Shah — Store Codes to PACS for JAKs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1994223 — (tier 1)
[S5] PMBJP crosses ₹1,000 crore sales in FY 2023-24 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1988675 — (tier 1)
[S6] 16,912 JAKs by 30.6.2025; 25,000 target by March 2027 — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2149782 — (tier 1)
[S7] PM interaction with PMBJP beneficiaries on Jan Aushadhi Diwas (2019) — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=1605670 — (tier 1)
[S8] 15,057 JAKs by 28.2.2025 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2114994 — (tier 1)